Subject: Thermography and Breast Specific Gamma Imaging for the Detection of Breast Lesions		Original Effective Date: 12/11/13
Policy Number: MCP-127	**Revision Date(s):** 1/1/16	
Review Date: 12/16/15, 6/22/17, 3/8/18, 6/19/19		
MCPC Approval Date: 3/8/18, 6/19/19		

DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Policy (MCP) document and provide the directive for all Medicare members.

DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL [40]

Mammography is considered the gold standard for breast cancer screening and the most effective means for detecting breast cancer when combined with breast self-examination. Approximately three fourths of lesions identified on mammograms have a benign biopsy outcome therefore thermography in general, and infrared imaging (IRI) in particular, have been developed as a safe, noninvasive adjunct to, rather than a replacement for, mammography to improve early detection and avoid unnecessary biopsy. Since thermography provides results more quickly than biopsy, it has the potential to prevent unnecessary concern after a positive mammogram. Another feature of thermography is that, unlike mammography and some other adjunctive tests, it detects physiological rather than anatomical changes.

Thermographic devices measure infrared energy emanating from the surface of the skin and display heat or temperature in the form of a colored pattern. Warmer regions of skin may indicate the presence of precancerous tissue or tumors since tissue temperature rises due to angiogenesis and other physiological changes associated with tumor development. Like other imaging modalities, thermography is a screening rather than a diagnostic test. A diagnosis of breast cancer must be confirmed with a biopsy. Since thermography is designed to detect physiological changes that occur in very early-stage breast cancer, it may detect tumors that other modalities would miss and some evidence suggests that thermography can identify patients at risk for breast cancer.

Breast-specific gamma imaging (BSGI) was developed as a confirmatory test to be used in conjunction with mammography and a clinical breast examination. Unlike mammography, the sensitivity of BSGI is not affected by breast tissue density, breast implants, or scars. BSGI differentiates normal and abnormal breast tissue based on the differential uptake of technetium-99m (99mTc) sestamibi, a radioactive agent that accumulates in malignant breast tissue due to increased vascularity and mitochondrial activity. BSGI was initially performed using general nuclear medicine gamma cameras which had large fields of view and resultant low sensitivity. The Dilon 6800 Gamma Camera, with high resolution and a small field of view, was specially designed for this imaging. BSGI is typically performed on an outpatient basis by a nuclear medicine technician who has been trained in breast positioning. It takes between 45 and 60 minutes. Approximately 5 to 10 minutes after intravenous injection of 25 to 30 mCi (millicuries) of 99mTc-sestamibi, each breast undergoes two 10-minute imaging sessions. One image is taken in the mediolateral plane and the other in the craniocaudal plane. During each 10-minute period of imaging, the gamma camera is continuously pressed against one side of the breast, which is mildly compressed. Additional views may be ordered as needed. Results are interpreted by a radiologist or a nuclear medicine physician.

RECOMMENDATION

- ❑ Thermography also referred to as digital infrared thermal imaging (DITI) and temperature gradient studies for the diagnosis of breast lesions is considered experimental, investigational and unproven because there is insufficient clinical evidence to determine whether the sensitivity and/or specificity of diagnosis improved when thermography was combined with mammography, or whether breast thermography improves health outcomes.

- ❑ Breast specific gamma imaging (BSGI) also known as molecular breast imaging or scintimammography for the diagnosis of breast lesions is considered experimental, investigational and unproven because the available evidence has not conclusively demonstrated that BSGI is more effective than US or MRI for evaluation of suspicious breast lesions detected by mammography or clinical breast examination.

SUMMARY OF MEDICAL EVIDENCE [10-37]

Breast Thermography [10-17]

The published evidence includes comparative studies that evaluated the diagnostic accuracy of dynamic infrared imaging (DIRI) or infrared imaging (IRI) with diagnoses confirmed by biopsy and uncontrolled studies. The study results suggest that DIRI has high sensitivity and poor to moderate specificity for detection of breast cancer. In the largest studies, DIRI had 97% to 98% sensitivity, indicating that it detected almost all of the breast cancers. However, the specificity was 14% in the largest study [10] and 55% in a second study, [16] which suggests that, like mammography, DIRI incorrectly identifies many benign masses as being malignant. Only one study evaluated the diagnostic efficacy of IRI, finding that it had 83% sensitivity and 81% specificity.[12] Although this study found that IRI combined with mammography and clinical breast examination had 98% sensitivity, the investigators did not report whether this outcome was statistically significant. Moreover, the specificity of this combination of tests was not reported. None of the available studies determined whether the sensitivity and/or specificity of diagnosis improved when DIRI was combined with mammography, or whether

breast thermography improves health outcomes. Therefore, there is insufficient clinical evidence to determine whether the sensitivity and/or specificity of diagnosis improved when thermography was combined with mammography, or whether breast thermography improves health outcomes.

Breast specific gamma imaging (BSGI) [18-29]

The published evidence includes comparative studies that evaluated BSGI for detection of breast cancer and uncontrolled studies that evaluated its influence on post biopsy patient management. Sensitivity ranged from 89% to 100% and specificity ranged from 60% to 90%. [18-22] Results of the available studies do not provide conclusive evidence that BSGI should be relied on as a replacement for biopsy, US, or MRI in women who have suspicious breast lesions on mammograms. In several of the studies, BSGI detected some cancerous lesions that were not detected by mammography; however, these studies did not report whether the increased detection corresponded to a statistically significant increase in the sensitivity of BSGI compared with mammography. In the studies that provided data on patient management, BSGI was not rigorously compared with MRI or US to determine whether it was more effective. Only two studies reported the statistical significance of results, both of which indicated that BSGI was more specific than MRI. The available evidence has not conclusively demonstrated that BSGI is more effective than US or MRI for evaluation of suspicious breast lesions detected by mammography or clinical breast examination.

Professional Organizations [4-9]

Several professional organizations have not endorsed or have not mentioned thermography and/or breast specific gamma imaging as standard diagnostic tests for the detection of breast lesions. ACR appropriateness criteria mentions that there have been no large population studies of molecular breast imaging (MBI) for screening, and the whole-body radiation dose with this technique is concerning.

CODING INFORMATION: THE CODES LISTED IN THIS POLICY ARE FOR REFERENCE PURPOSES ONLY. LISTING OF A SERVICE OR DEVICE CODE IN THIS POLICY DOES NOT IMPLY THAT THE SERVICE DESCRIBED BY THIS CODE IS COVERED OR NON-COVERED. COVERAGE IS DETERMINED BY THE BENEFIT DOCUMENT. THIS LIST OF CODES MAY NOT BE ALL INCLUSIVE.

CPT	Description: There are no CPT codes which specifically describe BSGI or breast thermography
78800	Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); limited area (when used for BSGI)
78801	Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); multiple areas (when used for BSGI)
93740	Temperature gradient studies (when used for breast thermography)
HCPCS	**Description: There are no HCPCS codes which specifically describe BSGI or breast thermography**
A9500	Imaging agent; Technetium TC 99M sodium gluceptate, diagnostic, per study dose up to 25 millicurie (when used for BSGI)
S8080	Scintimammography (radioimmunoscintigraphy of the breast, unilateral), including supply of Radiopharmaceutical (when used for BSGI)

ICD-10	Description: [For dates of service on or after 10/01/2015]
C50-C50.929	Malignant neoplasm of the breast

RESOURCE REFERENCES

Government Agency

1. Centers for Medicaid and Medicare (CMS). NCD #220.11. Thermography. Dec 21, 1992. Accessed at: https://www.cms.gov/medicare-coverage-database/
2. Food and Drug Administration (FDA). Center for Devices and Radiological Health. [Website]. Searchable 510(k) database scanned for product codes IYM (Telethermographic system) and LHQ (Telethermographic system for adjunctive use). Accessed at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
3. U.S. Preventive Services Task Force (USPSTF). Screening for breast cancer. 2016. Accessed at: http://www.uspreventiveservicestaskforce.org

Professional Society Guidelines

4. American Cancer Society (ACS). Guidelines for the Early Detection of Cancer. 2018. Accessed at: https://www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html
5. American Cancer Society (ACS). Newer and Experimental Breast Imaging Tests. 2018. Accessed at: https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/experimental-breast-imaging.html
6. American College of Obstetricians-Gynecologists. Practice Bulletin no. 179. Breast Cancer Risk Assessment and Screening in Average-Risk Women. Updated July, 2017. Accessed at: https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Gynecology/Breast-Cancer-Risk-Assessment-and-Screening-in-Average-Risk-Women
7. Breast Thermography SBI (Society of Breast Imaging) Position Statement. 2018. Accessed at: http://www.sbi-online.org/RESOURCES/PolicyPositionStatements/Breast_Thermography.aspx
8. American College of Radiology (ACR).
    - Appropriateness Criteria Breast Cancer Screening. Revised 2017. Accessed at: https://acsearch.acr.org/list
    - Practice Parameter for the Performance of Molecular Breast Imaging (MBI) using a Dedicated Gamma Camera. 2017. Accessed at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MBI.pdf
    - Appropriateness Criteria Palpable Breast Masses. 2016. Accessed at: https://acsearch.acr.org/docs/69495/Narrative/
9. National Comprehensive Cancer Network® NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer Screening and Diagnosis (V.2.2018). NCCN website: Accessed at: https://www.nccn.org/professionals/physician_gls/

Peer Reviewed Literature

10. Parisky YR, Sardi A, Hamm R, et al. Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions. AJR Am J Roentgen*ol*. 2003;180(1):263-269.
11. Keyserlingk JR, Ahlgren PD, Yu E, Belliveau N. Infrared imaging of the breast: Initial reappraisal using high-resolution digital technology in 100 successive cases of stage I and II breast cancer. Breast Journal. 1998;4(4):245-251.

12. Kontos M, Wilson R, Fentiman I. Digital infrared thermal imaging (DITI) of breast lesions: sensitivity and specificity of detection of primary breast cancers. Clin Radiol. 2011 Jun;66(6):536-9. Epub 2011 Mar 5.
13. Arora N, Martins D, Ruggerio D, Tousimis E, Swistel AJ, Osborne MP, et al. Effectiveness of a noninvasive digital infrared thermal imaging system in the detection of breast cancer. Am J Surg. 2008 Oct;196(4):523-6.
14. Fitzgerald A, Berentson-Shaw J. Thermography as a screening and diagnostic tool: a systematic review. N Z Med J. 2012 Mar 9;125(1351):80-91.
15. Vreugdenburg TD, Willis CD, Mundy L, Hiller JE. A systematic review of elastography, electrical impedance scanning, and digital infrared thermography for breast cancer screening and diagnosis. Breast Cancer Res Treat. 2013 Feb;137(3):665-76. doi: 10.1007/s10549-012-2393-x. Epub 2013 Jan 4.
16. Arena F, Barone C, DiCicco T. Use of digital infrared imaging in enhanced breast cancer detection and monitoring of the clinical response to treatment. Conference Proceedings. 25th Annual International Conference of the Engineering in Medicine and Biology Society. September 17-21, 2003. Cancun, Mexico.
17. Amalu WC. Nondestructive testing of the human breast: the validity of dynamic stress testing in medical infrared breast imaging. Conference Proceedings. 26th Annual International Conference of the Engineering in Medicine and Biology Society. September 1-5, 2004. San Francisco, CA. Available at: http://www.breastthermography.com/research_studies.htm.
18. Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol. 2007b;14(8):945-950.
19. Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer [correction appears in Radiology. 2009;251(1):308]. Radiology. 2008;247(3):651-657.
20. Brem RF, Ioffe M, Rapelyea JA, et al. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol. 2009;192(2):379-383. Available at: http://www.ajronline.org/content/192/2/379.long.
21. Brem RF, Petrovitch I, Rapelyea JA, Young H, Teal C, Kelly T. Breast-specific gamma imaging with 99mTc-Sestamibi and magnetic resonance imaging in the diagnosis of breast cancer--a comparative study. Breast J. 2007a;13(5):465-469.
22. Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology. 2005;237(1):274-280. Available at: http://radiology.rsna.org/content/237/1/274.long.
23. Killelea BK, Gillego A, Kirstein LJ, et al. George Peters Award: How does breast-specific gamma imaging affect the management of patients with newly diagnosed breast cancer? Am J Surg. 2009;198(4):470-474.
24. Weigert JM, Bertrand ML, Lanzkowsky L, Stern LH, Kieper DA. Results of a multicenter patient registry to determine the clinical impact of breast-specific gamma imaging, a molecular breast imaging technique. AJR Am J Roentgenol. 2012;198(1):W69-W75.
25. O'Connor M, Rhodes D, Hruska C. Molecular breast imaging. Expert Rev Anticancer Ther 2009; 9:1073.
26. Zhou M, Johnson N, Gruner S, et al. Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient. Am J Surg 2009; 197:159.
27. Kim BS. Usefulness of breast-specific gamma imaging as an adjunct modality in breast cancer patients with dense breast: a comparative study with MRI. Ann Nucl Med. 2012;26(2):131-137.

28. Siegal E, Angelakis E, Morris P, Pinkus E. Breast molecular imaging: a retrospective review of one institutions experience with this modality and analysis of its potential role in breast imaging decision making. Breast J. 2012;18(2):111-117.
29. Tadwalkar RV, Rapelyea JA, Torrente J, et al. Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade. Br J Radiol. 2012;85(1014):e212-e216.

Updated Literature Review 2019

30. Alikhassi A, Hamidpour SF et al. Prospective comparative study assessing role of ultrasound versus thermography in breast cancer detection. Breast Dis. 2018;Apr 9.
31. Neal CH, Flynt KA et al. Breast imaging outcomes following abnormal thermography. Acad Radiol. 2018;Mar;25(3):273-278.
32. Omranipour R, Kazemian A et al. Comparison of the accuracy of thermography and mammography in the detection of breast cancer. Breast Care (Basel). 2016;Aug;11(4):260-264.
33. Zare I, Ghafarpour A et al. Evaluating the thermal imaging system in detecting certain types of breast tissue masses. Biomedical Research. 2016;27(3):670-675.
34. Prasad SS, Ramachandra L et al. Evaluation of efficacy of thermographic breast imaging in breast cancer: a pilot study. Breast Dis. 2016;36(4):143-147.
35. Choi EK, Im JJ et al. Usefulness of feature analysis of breast-specific gamma imaging for predicting malignancy. Eur Radiol. 2018 Jun 12. doi: 10.1007/s00330-018-5563-3. [Epub ahead of print]
36. Zhang XH, Xiao C. et al. Diagnostic Value of Nineteen Different Imaging Methods for Patients with Breast Cancer: a Network Meta-Analysis. Cell Physiol Biochem. 2018;46(5):2041-2055. doi: 10.1159/000489443. Epub 2018 Apr 28.
37. Huppe AI, et al. Molecular breast imaging: a comprehensive review. Semin Ultrasound CT MR 2018 Feb;39(1):60-69.

Other Resources

38. Advanced Medical Review (AMR): Policy reviewed by practicing board certified radiologist. 11/13/2013.
39. UpToDate: [Website] Waltham, MA: Walters Kluwer Health; 2019
    - Elmore J. Screening for Breast Cancer: Evidence for effectiveness and Harms.
    - Elmore J. Screening for Breast Cancer. Strategies and recommendations.
    - Slantez P. MRI of the breast and emerging technologies.
40. Hayes. Winifred Hayes Inc. Lansdale PA.
    - Search & Summary. Digital Infrared Imaging (Thermography) for Breast Cancer Screening. Aug, 2018.
    - Health Technology Brief Report. Digital Infrared Imaging (Thermography) for Detection of Breast Cancer. July 2006, archived Aug 6, 2009.
    - Hayes Health Technology Brief Report. Breast-Specific Gamma Imaging (BSGI) using the Dilon 6800 Gamma Camera (Dilon Technologies Inc.). Updated July, 2014. Archived 2015.
41. ECRI Evidence Report. Breast-Specific Gamma Imaging for Breast Cancer. March, 2013. Accessed at: https://www.ecri.org/components/EvidenceReports/Pages/12861.aspx

Revision/Review History:

12/11/13: Policy created
12/16/15: Policy reviewed, no changes

1/1/16: Policy reviewed and revised to include Breast-specific gamma imaging (BSGI) which is another test used for breast cancer screening. Both Thermography and BSGI are outlined as experimental, investigational breast cancer screening tests.
3/8/18: Policy reviewed, clinical criteria has not changed.
6/19/19: Policy reviewed, clinical criteria has not changed. Both Thermography and BSGI continued to be experimental, investigational breast cancer screening tests based on current literature. Updated literature, references and professional society guidelines.